Authors
Sabrina Paganoni, James D Berry, Melanie Quintana, Eric Macklin, Benjamin R Saville, Michelle A Detry, Marianne Chase, Alexander V Sherman, Hong Yu, Kristin Drake, Jinsy Andrews, Jeremy Shefner, Lori B Chibnik, Matteo Vestrucci, Merit E Cudkowicz, Healey ALS Platform Trial Study Group, HEALEY ALS Platform Trial Study Group, Biostatisticians, Eric Macklin, Melanie Quintana, Ben Saville, Michelle A Detry, Lori Chibnik, Marie Abele Bind, James Chan, Matteo Vestrucci, Investigators, Eduardo Locatelli, Gustavo Alameda, Sabrina Paganoni, Merit Cudkowicz, Alexandra McCaffrey, James Berry, Suma Babu, Katie Nicholson, Jennifer Scalia, Zachary Simmons, James Grogan, Xiaowei Su, Mansoureh Mamarabadi, Daragh Heitzman, Mohamad Asaad Nasri, Jonathan Katz, Liberty Jenkins, Kevin Felice, Charles Whitaker, Senda Ajroud‐Driss, Adam Quick, Stephen Kolb, NP Sarah Heintzman, Stanley H Appel, Ericka Greene, Jason Thonhoff, Sheetal Shroff, Bing Liao, Stephen A Goutman, Eva L Feldman, Timothy Miller, NP Amber Malcolm, Daniel S Newman, Ximena Arcila‐Londono, Kara Steijlen, Margaret Ayo Owegi, Robert H Brown Jr, Mehdi Ghasemi, Joseph Americo M Fernandes, Ezequiel Piccione, Pariwat Thaisetthawatkul, Michael D Weiss, Nassim Rad, Hristelina Ilieva, Piera Pasinelli, NP Judith Guarnieri, Shafeeq Ladha, Bill Jacobsen, Robert Bowser, Jeremy Shefner, Laura Foster, Carlayne Jackson, Jeffrey Rosenfeld, Karthikeyan Bhuvaneswaran, Lauren Elman, Colin Quinn, Jinsy Andrews, NP Julia Yasek, Dominic Fee, Terry Heiman‐Patterson, Anahita Deboo, Andrea Swenson, Christopher Nance, Tuan Vu, Niraja Suresh, Jerrica Farias, Jim Caress, Michael Cartwright, Kourosh Rezania, Matthew Elliott, Seward Rutkove, Courtney McIlduff, Jeffrey A Cohen, Elijah Stommel, Jonathan Glass, Christina Fournier, Eufrosina Young, James P Wymer, Volkan Granit, Michael Benatar, Richard Lewis, Matthew Burford, Frank Diaz, Nicholas J Maragakis, Lora Clawson, Alpa Uchil, Kristen Riley, Betsy Mosmiller, Paul Twydell, Namita A Goyal, Omar Jawdat, Duaa Jabari, Jeffrey Statland, Edward J Kasarskis, James W Russell, Peter Jin, David Walk, Sam Maiser, Jaimin Shah, Bjorn Oskarsson, Richard Bedlack, Xiaoyan Li, I‐Hweii Amy Chen, Nicholas Olney, Tracy Bazan, Ghazala Hayat, Gary L Pattee, Peter D Donofrio, Amanda C Peltier, Jennifer Martinez‐Thompson, Nathan, Kristin Johnson, Raghav Govindarajan, Vovanti Jones, Tulio Bertorini, Clotilde Lagier Tourenne, Ghazaleh Sadri Vakili, Clinical Operations Team, Marianne Chase, Alex Sherman, Hong Yu, Derek Dagostino, Scott Bocchio
Publication date
2022/2
Source
Annals of neurology
Volume
91
Issue
2
Pages
165-175
Publisher
John Wiley & Sons, Inc.
Description
Current therapeutic development in amyotrophic lateral sclerosis (ALS) relies on individual randomized clinical trials to test a specific investigational product in a single patient population. This approach has intrinsic limitations, including cost, time, and lack of flexibility. Adaptive platform trials represent a novel approach to investigate several interventions for a single disease in a continuous manner. Already in use in oncology, this approach is now being employed more often in neurology. Here, we describe a newly launched platform trial for ALS. The Healey ALS Platform Trial is testing multiple investigational products concurrently in people with ALS, with the goal of rapidly identifying novel treatments, biomarkers, and trial endpoints. ANN NEUROL 2022;91:165–175
Total citations
Scholar articles
S Paganoni, JD Berry, M Quintana, E Macklin… - Annals of neurology, 2022